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Recent events have made it clear that potentially pandemic strains of influenza regularly 
pose a threat to human populations. Therefore, it is essential that we develop better 
strategies to enhance vaccine design and evaluation to predict those that will be poor 
responders to vaccination and to identify those that are at particular risk of disease-as-
sociated complications following infection. Animal models have revealed the discrete 
functions that CD4 T cells play in developing immune response and to influenza immu-
nity. However, humans have a complex immunological history with influenza through 
periodic infection and vaccination with seasonal variants, leading to the establishment 
of heterogeneous memory populations of CD4 T cells that participate in subsequent 
responses. The continual evolution of the influenza-specific CD4 T cell repertoire involves 
both specificity and function and overlays other restrictions on CD4 T cell activity derived 
from viral antigen handling and MHC class II:peptide epitope display. Together, these 
complexities in the influenza-specific CD4 T cell repertoire constitute a formidable obsta-
cle to predicting protective immune response to potentially pandemic strains of influenza 
and in devising optimal vaccine strategies to potentiate these responses. We suggest 
that more precise efforts to identify and enumerate both the positive and negative con-
tributors within the CD4 T cell compartment will aid significantly in the achievement of 
these goals.
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tHe sPeciFicitY OF HUMAN cD4 t ceLLs tO iNFLUeNZA 
virUs
It has become increasingly clear that CD4 T cell immunity to influenza has broad specificity (1–4). 
CD4 T cells specific for influenza viral proteins can be readily detected in the circulation of most 
human subjects, when assayed through approaches, such as HLA-class II tetramer staining (5), 
intracellular cytokine staining (6), and cytokine Elispots (7). Our laboratory has used cytokine 
Elispots and large peptide libraries to assess the viral protein specificity of influenza-specific CD4 
T cells in an unbiased approach (8, 9). Figure  1A shows the results from the sampling of CD4 
FiGUre 1 | Patterns of human cD4 t cell reactivity to influenza viral proteins in healthy subjects. In (A), IFN-γ Elispots were used to enumerate 
antigen-reactive CD4 T cells. CD4 T cells isolated from eight healthy adults were tested for reactivity to individual proteins using overlapping peptide pools 
representing the entire translated sequence of the indicated influenza protein. The relative reactivity to each protein is represented in a pie diagram, with each viral 
protein indicated by a different color and the percent of the total influenza response in the different subjects indicated by the size of the slice. In (B), CD4 T cell 
reactivity to different seasonal and pandemic HA peptide pools were compared. Reactivity to pH1N1 HA protein was determined using the pre-vaccination reactivity 
of 49 healthy adult donors (9, 13). Reactivity to avian proteins was determined using baseline reactivity of a panel of 30 (H5) and 23 (H7) seronegative donors, 
enrolled as part of pandemic vaccine studies (12). (c) shows the amino acid sequence conservation for viral HA, NP, and M1 proteins. Yellow bars represent 
segments of sequence variation and black segments denote stretches of sequence identity at each position. Viral isolates for each HA subtype are as follows: 
H1 – A/Brisbane/59/2007 (H1N1), pH1 – A/California/07/2009 (H1N1), H5 – A/Vietnam/1203/2004 (H5N1), H3 – A/Texas/50/2012 (H3N2), and H7 – A/
Anhui/1/2013 (H7N9), where italics indicate divergent viruses with pandemic potential to humans. Viral isolates for NP and M1 are as follows: H1N1 – A/Puerto 
Rico/8/1934, pH1N1 – A/California/07/2009, H5N1 – A/Vietnam/PEV16T/2005, and H7N9 – A/Anhui/1/2013. Sequence files were downloaded from PubMed and 
conservation profiles were constructed using CLC Sequence Viewer 7 software.
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T cells isolated from PBMC of healthy adults for reactivity to 
influenza viral proteins, including hemagglutinin (H1 and H3), 
neuraminidase (N1 and N2), nucleoprotein (NP), and matrix 
1 (M1) from seasonal isolates (8). These studies have revealed 
abundant CD4 T cell reactivity to most influenza viral proteins, 
with variable frequency, typically in the range of 0.03–0.4% of 
the total circulating pool when all specificities are summed. This 
finding of a broad CD4 T cell repertoire to influenza is in agree-
ment with our studies in animal models that show that CD4 T 
cells elicited in response to infection (4, 8, 10) and vaccination 
(11, 12) include specificity for almost all viral proteins, depending 
on the host’s MHC class II proteins. Humans have many options 
for HLA class II molecules to present peptides to CD4 T cells due 
to multiple isotypes (HLA-DP, HLA-DQ, and HLA-DR), their 
codominant expression and heterozygosity. Therefore, their CD4 
T cell repertoire is likely broader than inbred mice. This diversity 
of influenza-specific CD4 T cells in humans has raised intriguing 
issues and challenges relevant for predicting vaccine responses 
and protection from influenza infection.
tHe MULtiPLicitY OF FUNctiONs OF 
iNFLUeNZA-sPeciFic cD4 t ceLLs
Many functions of influenza-specific CD4 T cells have been 
described (14–17). Collectively, these studies have revealed that 
CD4 T cells contribute in diverse ways and at different sites in vivo 
to protective immunity to influenza. CD4 T cells provide essential 
help for high-affinity, neutralizing antibody responses, an activ-
ity conveyed by CD4 T follicular helper cells (Tfh) within the 
germinal centers of secondary lymphoid organs (18–22). Within 
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the draining lymph node, CD4 T cells can also enhance the 
recruitment of other effector cells, facilitate engagement of CD8 
T cells with dendritic cells, and promote CD8 T cell priming and 
memory. Moreover, CD4 T cells can engage in direct cytotoxicity 
of antigen bearing cells, a function suggested to be the primary 
correlate of protection from infection in humans (23). Finally, 
within the lung, memory CD4 T cells provide diverse functions 
including production of antiviral cytokines, such as IFN-γ, pro-
motion of early recruitment of innate effectors, and potentiation 
of CD8 T cell recruitment, localization, and persistence (24–26).
This multiplicity of potential functions contributed by memory 
CD4 T cells, each conferred by distinct arrays of soluble media-
tors and cell surface proteins, presents a significant challenge for 
predicting and enhancing protective immunity to potentially 
pandemic strains of avian influenza. In our view, several key ques-
tions need to be resolved in order to better understand the impact 
of CD4 T cells on human immunity to influenza infection. The first 
is whether different specificities of influenza-reactive CD4 T cells 
convey different functions. We hypothesize and have supporting 
evidence that the functional potential of CD4 T cells may be 
linked to both the fine specificity and the viral protein of origin. 
Second, under what circumstances are particular effector func-
tions of CD4 T cells the limiting factor in the protective response? 
These limiting functions would be those that need to be moni-
tored in susceptible hosts pre- and postinfection and enhanced 
by vaccination. Finally, to what degree do the different CD4 T 
cell subsets and their potentially unique specificities regulate each 
other’s function and how much do these interactions confound 
efforts to quantify the contribution of CD4 T cells to influenza 
immunity? We will discuss these issues and our own work that 
sheds light on them below.
LiNKs BetWeeN sPeciFicitY AND 
FUNctiON OF cD4 t ceLLs iN 
iNFLUeNZA
Because of the importance of neutralizing antibodies in protec-
tion from influenza, we have explored the role of viral protein 
specificity in provision of CD4 T cell help for antibody responses 
to vaccines and infection. Several studies have shown that Tfh 
cells can be a limiting factor in the B cell response (27–29). We 
used a mouse model utilizing synthetic peptides (previously 
identified to be co-immunodominant) to generate CD4 T cell 
memory independently of B cell activation. These studies revealed 
an inseparable linkage of specificity in the provision of CD4 T 
cell help to antigen-specific B cells (30), a result in agreement 
with earlier studies using vaccinia virus (31). We found that mice 
with CD4 memory to NP demonstrated an enhanced antibody 
response to NP, but not HA, while those with CD4 T cell memory 
to HA exhibited an accelerated antibody response to HA, a phe-
notype associated with lower viral titers in the lungs. We interpret 
this important result to mean that HA-specific memory CD4 T 
cells can potentiate early neutralizing antibody production that 
can diminish the yield of infectious virus.
Our studies of the human response to influenza vaccina-
tion agree with and extend this concept of linked specificity to 
vaccination. Although licensed vaccines are quantified only for 
HA from the manufacturers, inactivated vaccines produced in 
embryonated chicken eggs also contain the membrane protein 
NA and internal viral proteins, such as M1 and NP (32, 33). The 
presence of these additional viral proteins has been detected by 
both biochemical and functional assays. Therefore, these vaccines 
will recruit CD4 T cells specific for many viral proteins, some 
of which are novel (i.e. HA and NA) and some conserved (i.e. 
NP and M1). The consequences of boosted memory CD4 T cells 
competing with naïve CD4 T cells specific for novel epitopes 
within HA and NA is not known, nor do we understand if all 
CD4 T cells elicited by the vaccine will promote production of 
protective antibodies. In two separate studies, we have tracked 
the expansion of human CD4 T cells after vaccination, using 
cytokine Elispots and large peptide pools derived from discrete 
viral proteins that bypass the need for antigen processing. When 
CD4 T cell responses were tracked over time, we found that 
expansion of CD4 T cells specific for peptide epitopes within HA, 
but not NP, positively correlated with the neutralizing anti-HA 
antibody response (9, 12). We speculate that the form of antigen 
taken up by HA-specific B cells after vaccination and after infec-
tion does not include NP. According to this model, the specificity 
of recruited CD4 T cells to facilitate the neutralizing antibody 
response is dependent on the nature of the antigen internalized 
by HA-specific B cells.
We have also found an intriguing difference between the func-
tional potential of HA- and NP-specific CD4 cells through the 
analyses of specificity in “Tfh-like” cells and non-Tfh cells in the 
circulation of healthy adults. Antigen-experienced CD4 T cells 
were separated based on expression of the prototypic marker of 
Tfh, CXCR5, a chemokine receptor shown to be expressed on a 
subset of circulating human CD4 T cells that likely represents cir-
culating memory Tfh (34–36). We (37) and others (38) found that 
CXCR5+ CD4 T cells were selectively able to promote antibody 
production when cocultured with naïve B cells (36). Interestingly, 
when examined for influenza specificity, CXCR5+ Tfh-like cells 
were enriched for reactivity to HA, whereas CXCR5− non-Tfh 
cells were preferentially reactive to NP. This pattern, detected 
by both cytokine Elispots and a cytokine-independent assay, 
was observed in multiple individuals, each presumably with a 
distinct history of infection and vaccination. Collectively, these 
results suggest that HA-specific CD4 T cells likely have the most 
potential to provide help for neutralizing antibody responses and 
may be the most critical to monitor pre- and post-vaccination. 
CD4 T cells specific for other viral proteins, such as NP, may not 
only fail to provide help but may also be preferentially associated 
with alternative effector programs, including expression of IFN-γ 
and CXCR3.
tHe cHALLeNGe tO sUccessFUL 
vAcciNAtiON AND PrOtectiON FrOM 
NOveL, PANDeMic strAiNs OF 
iNFLUeNZA
The preceding findings regarding the link between HA specificity 
of CD4 T cells and antibody responses are of particular importance 
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when considering the ability of circulating CD4 memory to pro-
vide help for protection against novel and potentially pandemic 
strains of influenza. Shown in Figure 1C is the comparison of the 
extent of sequence identity between influenza proteins derived 
from seasonal strains and potentially pandemic strains (pH1N1, 
H5N1, and H7N9), where yellow represents divergence of the 
potentially pandemic strain from the indicated seasonal strain. It 
is clear from this comparison that M1 and NP offer more regions 
of sequence identity than does HA and thus more potential for 
cross-reactive CD4 T cell recognition of potential pandemic 
strains. Others have identified such cross-reactive CD4 T cells 
(39–42). However, our results, thus far, suggest that many of 
these CD4 T cells, specific for internal virion proteins, may not 
contribute positively to the antibody response following infection 
or vaccination.
It is our view that for provision of help for neutralizing 
antibody responses to pandemic influenza, HA-specific cells 
may be the most critical. In the host that has not previously 
encountered a new and potentially pandemic strain of influenza, 
these HA-specific CD4 T cells must be drawn from the memory 
pool elicited previously by seasonal strains. We have found that 
the relatively small pool of HA-specific memory CD4 cells that 
can be recruited into the response to novel strains of influenza 
will vary among individuals, likely reflecting their exposure 
history with seasonal influenza. The potential for cross reactive 
recognition by HA specific CD4 T cells will also depend on the 
relatedness between the HA proteins, clear from the comparison 
of Figures 1B,C. For example, the pandemic strain of influenza 
(“pH1N1”) that emerged in 2009 expressed a novel H1 HA 
protein originally encoded within a classic swine influenza strain 
(43–46). Because this HA was an H1 protein, there was significant 
(79%) sequence identity with recently circulating seasonal H1 
HA proteins. In agreement with this, using a murine model, we 
demonstrated that infection with seasonal H1N1 established sub-
stantial numbers of memory CD4 T cells that could be mobilized 
and provide protection upon infection with the pH1N1 strain 
(47). We (9) and others (48, 49) have also shown that vaccina-
tion of humans with a monovalent pH1N1 vaccine successfully 
elicited neutralizing antibody responses despite very little B cell 
cross-reactivity, suggesting that the memory CD4 T cells were 
able to facilitate a primary B cell response to unique pH1 epitopes. 
The pH1N1 vaccine elicited a robust HA-specific CD4 T cell 
response primarily drawn from memory CD4 T cells specific 
for peptides shared between the seasonal and pandemic strain. 
Moreover, expansion of CD4 T cells specific for these conserved 
HA epitopes was the best CD4 T cell correlate of the neutralizing 
antibody response (9). We suspect that this greater degree of CD4 
T cell cross-reactivity may be responsible for the better antibody 
response to pH1N1 vaccination compared to avian influenza-
derived vaccines and may also have served to temper disease 
progression during the initial spread of this virus.
The challenge for provision of CD4 T cell help for antibody 
responses to novel strains of influenza is much more profound for 
avian strains than the pH1N1 2009 strain. Numerous reports have 
documented the “poor immunogenicity” of avian-derived influ-
enza vaccines (50–52) unless administered at high doses or with 
adjuvants (53, 54). The reasons underlying these vaccine failures 
are not completely clear, but it seems likely that this is in part due 
to the lack of cross-reactive B and CD4 T cell memory. It has been 
well documented that memory T and B cells are preferentially 
recruited into immune responses (55–57). These advantages 
likely reflect greater numbers of lymphocytes, lower TcR signal-
ing thresholds as well as less reliance on the costimulatory signals 
needed for initial activation of naïve lymphocytes. These factors 
collectively lead to their preferential recruitment into an immune 
response to pathogens or vaccines that simultaneously present 
both conserved and novel epitopes to the immune system. In fact, 
the presence of responses to conserved epitopes can antagonize 
the clonal expansion of naïve CD4 T cells specific for novel 
epitopes (13).
In an effort to understand the potential for seasonal influenza 
to establish memory CD4 T cells capable of being recruited 
into a subsequent response with avian H7 HA-derived CD4 T 
cell epitopes, we surveyed human subjects with no history of 
encounter with H7 viruses or vaccines. PBMC were isolated 
from these healthy adults, each with presumably distinct and 
complex immunological history with seasonal influenza. Among 
the 20 healthy adults analyzed, approximately 60% had readily 
detectable CD4 T cell reactivity to peptides derived from the H7 
HA protein and the vast majority of CD4 T cell reactivity was 
focused on epitopes contained within the carboxy-terminal half 
of the H7 protein (58). In individuals possessing CD4 T cells that 
cross-reacted with H7, reactivity was focused on several “hot 
spots” of the HA2 domain that represent some, but not all, of the 
regions of high sequence identity between H7 and seasonal HA, 
in particular H3. We concluded from these studies that memory 
CD4 T cells elicited by seasonal influenza can be recruited by 
H7-derived epitopes and are primarily drawn from epitopes in 
the seasonal strain that is the closest phylogenetic relative.
HOW DO We cONstrUct A tALLY 
sHeet tHAt WiLL PreDict tHe iMPAct 
OF MeMOrY cD4 t ceLLs tO 
cONtriBUte tO PrOtective iMMUNitY 
tO iNFLUeNZA?
Existing data suggest that routine encounter with seasonal 
influenza through infection or vaccination regularly boosts CD4 
T cells of many specificities, establishing memory cells that can 
cross-reactively recognize epitopes specific from potentially 
pandemic strains. These circulating influenza-reactive CD4 T 
cells are heterogeneous with regard to expression of chemokine 
receptors and the gene expression profiles linked to distinct effec-
tor functions. Only a fraction of these memory CD4 T cells have 
the specificity and effector characteristics needed to promote 
neutralizing antibody production. Therefore, only a subset of 
these circulating CD4 T cells can facilitate neutralizing antibody 
responses to the pandemic strain of influenza, while others either 
might not be recruited to the germinal center response at all or 
if they are, might antagonize development of the needed effector 
function. Antagonism of help by memory CD4 T cells of other 
specificities could be due to production of soluble inhibitors, 
such as IL-10, TGF-β, and IFN-γ. As influenza-specific CD4 T 
FiGUre 2 | Delineating the contribution of distinct cD4 t cell populations in protective antibody responses to influenza virus infection and 
vaccination. The circulating human CD4 T cell repertoire against influenza is indicated in Figure 1 as a pie diagram with each slice representing relative reactivity to 
different viral proteins. Colors indicate speculated roles for CD4 T cells of differing antigen specificity with red representing known positive impact, orange unknown 
at present but possible, blue competitive or antagonistic impact, and gray indicating no impact. (A,B) represent CD4 T cell responses that may be relevant for 
neutralizing antibody responses after infection with an H3N2 virus, where those specific for HA may be the best correlate of help. (B) represents the possibility that 
CD4 help for production of neutralizing antibody may only be conferred by a subset of the HA-specific cells after infection, perhaps characterized by expression of 
CXCR5. In (c), the possibility that after infection or vaccination, CD4 T cells specific for NA and M1, like those specific for HA may contribute to CD4 help for 
antibody responses because of their potential for physical interactions, leading to simultaneous uptake by HA-specific B cells. In (D), NP (blue) is viewed as a 
potentially negative factor in the antibody response, although it may participate in an alternative CD4 function.
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cells often have a dominated T helper 1 phenotype, IFN-γ is a 
prominent effector cytokine produced in response to infection. 
In addition to its proinflammatory activities, IFN-γ has a well-
characterized role in inducing the production of indoleamine 
2,3-dioxygenase (IDO) in dendritic cells and other antigen-pre-
senting cells. IDO in turn can promote tryptophan degradation, 
which can cause T cell apoptosis, diminish T cell proliferation, 
or through the by-products of tryptophan metabolism, can 
have many antagonistic effects (59–61). Although the complex 
regulatory pathways induced by IDO have largely been explored 
in the context of tumor-specific immunity and chronic infections, 
IFN-γ and IDO have been implicated in suppressing responses 
to influenza (62). Thus, cytokines produced by memory CD4 T 
cells have the potential to induce immunosuppressive pathways 
that can directly inhibit CD4 T cell expansion or act through 
induction of tolerogenic dendritic cells and conventional CD4 
T regulatory cells. Inhibition might therefore occur at the initial 
CD4 T cell-priming event needed to activate Tfh cells or by active 
suppression of the germinal center response, through the par-
ticipation of T follicular regulatory cells [reviewed in Ref. (63)].
Many questions arise from this model that seeks to quantify 
and predict the impact of memory CD4 on influenza immunity. If 
CD4 T cell help in the germinal center response is a major factor 
limiting the magnitude of the neutralizing antibody response, 
how many CD4 T cells are needed and what fraction of the circu-
lating memory will be recruited into response to vaccination? It is 
clear that only a subset of circulating CD4 T cells are competent 
to help B cells develop into antibody secreting cells in vitro, in 
particular, those CD4 T cells expressing CXCR5 and PD1 and 
lacking CXCR3 (36). Are circulating CD4 T cells bearing these 
markers the primary source of memory CD4 T cells recruited 
into the lymph node after vaccination? It is known that CD4 
T cells have considerable flexibility (64, 65), and it is possible 
that other subsets of memory CD4 T cells can develop helper 
activity during the response to vaccination. Also, because CD4 
T cell-dependent antibody responses require B cell display of 
peptide:class II complexes, it is important to resolve if other viral 
proteins, particularly other membrane-associated proteins, such 
as M1 and NA, become co-internalized with HA by HA-specific 
B cells. If so, these proteins will also contribute peptide:class II 
complexes that can recruit additional Tfh. Similarly, because 
NA-specific antibodies elicited in response to vaccination are 
known to be a correlate of protection (66), it will be important 
to quantify the CD4 T cells that can promote production of these 
protective antibodies. Also, does antigen specificity influence 
the ability of CD4 T cells to convey the other functions of CD4 
T cells in protective immunity to influenza? For example, does 
early vaccination and repeated antigen encounters, particularly 
with epitopes from highly conserved internal virion proteins, 
reinforce some functions of CD4 T cells that are associated with 
terminal effectors, such as cytolysis and gamma interferon pro-
duction? These functions may not contribute to helper activity 
but may be important for other protective responses. Harty and 
coworkers (67) have shown through animal models of sequential 
encounter of CD8 T cells with antigen in  vivo that the CD8 T 
cell transcriptome continually evolves with every “hit,” and we 
speculate that frequent infection or vaccination may promote a 
similar evolution in CD4 T cell function in humans.
These questions are illustrated schematically in Figure  2, 
where we show the entire “pie” of memory CD4 T cells specific 
for influenza, where each slice represents a given viral protein 
specificity. We suggest that only some “slices” of this pie may be 
relevant to count toward productive antibody responses; HA 
being the most well documented thus far and NP being the most 
notably non-contributory. Because they are also membrane-
associated, M1 and NA from infection or vaccines may be co-
internalized with HA and CD4 T cells specific for these proteins 
may be able provide help, if these cells are contained within the 
CXCR5+CXCR3− pools. Even within a given protein slice, there 
may be only subsets of cells that have the needed gene expression 
program and array of cell surface receptors to home to the lymph 
node and provide cognate help in the germinal center response. If 
this general model is correct, then there are only limited numbers 
of CD4 T cells that should be quantified for predicting future 
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responses to vaccination and whose representation should be 
the goal of vaccination. Others may be neutral (in gray) and yet 
others may be a negative correlate of protection. At the same time, 
alternative subsets of cells may be the most relevant to mitigate 
the severity of an established infection, for example, those that 
express CXCR3, which may allow them to be selectively recruited 
to the site of infection. Here, their cytotoxic potential or secretion 
of cytokines may have an independent antiviral effect or promote 
viral clearance through the recruitment of other early effectors 
into the lung. Much progress by many groups has contributed 
thus far to our understanding of CD4 T cell function in influenza 
immunity. We suggest, moving forward, that more focused efforts 
to link these functions to CD4 T cell specificity, to consider both 
positive and negative effects of CD4 T cells and to utilize animal 
models with existing immunological memory for vaccine trials 
will together provide an increased accuracy in predicting the 
consequences of human encounter with pandemic viruses and 
vaccines. These new insights should provide the knowledge 
necessary to design the most effective prepandemic vaccination 
regimens that can optimally promote neutralizing antibody 
production against potentially pandemic strains.
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